Ginkgolide B 50 mg | 99.39%
TargetMol
Ginkgolide B is a PAFR antagonist(IC50=3.6 μM) isolated from Ginkgo biloba.
More Information Supplier PageGinkgolide B
Search Results
Anagrelide hydrochloride 100 mg | Purity Not Available
TargetMol
Anagrelide hydrochloride (BL4162A) is a drug used for the treatment of essential thrombocytosis.
More Information Supplier PageAnagrelide hydrochloride
Anagrelide hydrochloride 10 mg | Purity Not Available
TargetMol
Anagrelide hydrochloride (BL4162A) is a drug used for the treatment of essential thrombocytosis.
More Information Supplier PageAnagrelide hydrochloride
BMS-813160 25 mg | 99.66%
TargetMol
BMS-813160 is the first dual CCR2/CCR5 antagonist to enter Clinical development for cardiovascular.
More Information Supplier PageBMS-813160
BMS-813160 10 mg | 99.66%
TargetMol
BMS-813160 is the first dual CCR2/CCR5 antagonist to enter Clinical development for cardiovascular.
More Information Supplier PageBMS-813160
BMS-813160 5 mg | 99.66%
TargetMol
BMS-813160 is the first dual CCR2/CCR5 antagonist to enter Clinical development for cardiovascular.
More Information Supplier PageBMS-813160
BMS-813160 1 mg | 99.66%
TargetMol
BMS-813160 is the first dual CCR2/CCR5 antagonist to enter Clinical development for cardiovascular.
More Information Supplier PageBMS-813160
Tenofovir alafenamide 25 mg | 99.00%
TargetMol
Tenofovir Alafenamide (GS-7340) is a nucleotide reverse transcriptase inhibitor (NRTI) and a novel ester prodrug of the antiretroviral tenofovir.
More Information Supplier PageTenofovir alafenamide
Thiazovivin 100 mg | Purity Not Available
TargetMol
Thiazovivin, a ROCK inhibitor (IC50: 0.5 μM), increases the survival rate of hESC.
More Information Supplier PageThiazovivin
Thiazovivin 2 mg | Purity Not Available
TargetMol
Thiazovivin, a ROCK inhibitor (IC50: 0.5 μM), increases the survival rate of hESC.
More Information Supplier PageThiazovivin